Aaron Koenig, MD, Sage Therapeutics Inc., Cambridge, MA, explains the rationale behind targeting the NMDA pathway for the treatment of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) using a new investigational compound, SAGE-718. Previous research has demonstrated a relative NMDA deficit early in the course of neurodegenerative diseases such as AD. SAGE-718 is a positive allosteric modulator of the NMDA receptor and treatment with SAGE-718 could restore NMDA tone and therefore improve symptoms of cognitive decline. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.